Form 8K Allogene Therapeutics Inc For: 15 April
- Investing.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Allogene Therapeutics Inc (ALLO)
Allogene Therapeutics Inc stock price live, this page displays NASDAQ ALLO stock exchange data. View the ALLO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Allogene Therapeutics Inc real time stock price chart below.
What Is the Allogene Therapeutics Inc Stock Price Today?
The Allogene Therapeutics Inc stock price today is 2.170.
What Is the Stock Symbol for Allogene Therapeutics Inc?
The stock ticker symbol for Allogene Therapeutics Inc is ALLO.
Is ALLO the Same as $ALLO?
$ALLO is a common way to refer to the Allogene Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Allogene Therapeutics Inc Trade On?
Allogene Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Allogene Therapeutics Inc a Good Stock to Buy?
Determining whether Allogene Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Allogene Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALLO quote. (ISIN: US0197701065)
What Is the Allogene Therapeutics Inc Stock Price Today?
The Allogene Therapeutics Inc stock price today is 2.170.
What Is the Stock Symbol for Allogene Therapeutics Inc?
The stock ticker symbol for Allogene Therapeutics Inc is ALLO.
Is ALLO the Same as $ALLO?
$ALLO is a common way to refer to the Allogene Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Allogene Therapeutics Inc Trade On?
Allogene Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Allogene Therapeutics Inc a Good Stock to Buy?
Determining whether Allogene Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Allogene Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALLO quote. (ISIN: US0197701065)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.850
2.175
52 wk Range
0.862
4.460
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.8502.175
52 wk Range
0.8624.460
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALLO Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
8.050
Upside
+270.97%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
- Form 424B5 Allogene Therapeutics Inc For: 15 April
- Investing.com
- Form 8K Allogene Therapeutics Inc For: 15 April
- Investing.com
- Form 424B5 Allogene Therapeutics Inc For: 15 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Allogene Therapeutics Inc SWOT Analysis
Analyst Outlook | Price targets range from $5 to $14, with an average of $9.33, reflecting varied perspectives on Allogene's growth potential and market position |
Market Dynamics | Explore Allogene's competitive edge in allogeneic CAR T therapy, facing challenges from established players and emerging technologies |
Financial Fortitude | Strong cash position of $302.6M extends runway to 2027, supporting ongoing clinical development amid absence of current revenue |
Pipeline Promise | Allogene's AlloCAR T therapies show potential in LBCL, RCC, and autoimmune diseases, with key trials advancing despite timeline adjustments |
Allogene Therapeutics Inc Earnings Call Summary for Q4/2025
- Allogene beat Q4 2025 EPS forecast at -$0.17 vs. -$0.23 expected, a 26% positive surprise; stock fell 6% to $2.61 in aftermarket trading.
- Company maintains $258.3M cash position extending runway into Q1 2028; received additional $23.7M from arbitration in February 2026.
- 2026 guidance projects operating cash expenses of ~$150M and GAAP operating expenses of ~$210M; 5 analysts revised earnings upward.
- ALPHA3 trial remains strategic priority with interim data expected April 2026; focus continues on ALPHA3 and RESOLUTION programs.
- Revenue forecast of $2.22B; executives emphasize operational discipline amid regulatory challenges in competitive CAR T therapy market.
Last Updated: 03/12/2026, 06:36 PM
Read Full TranscriptCompare ALLO to Peers and Sector
Metrics to compare | ALLO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALLOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.8x | −1.4x | −0.5x | |
PEG Ratio | −0.08 | −0.02 | 0.00 | |
Price / Book | 1.8x | 2.2x | 2.6x | |
Price / LTM Sales | - | 19.0x | 3.2x | |
Upside (Analyst Target) | 282.8% | 405.7% | 47.6% | |
Fair Value Upside | Unlock | 7.1% | 6.1% | Unlock |
Analyst Ratings
13 Buy
1 Hold
1 Sell
Ratings:
15 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 8.050
(+270.97% Upside)
Earnings
Latest Release
Mar 12, 2026
EPS / Forecast
-0.17 / -0.23
Revenue / Forecast
-- / 2.22K
People Also Watch
FAQ
What Is the Allogene Therapeutics (ALLO) Stock Price Today?
The Allogene Therapeutics stock price today is 2.170 USD.
What Stock Exchange Does Allogene Therapeutics Trade On?
Allogene Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Allogene Therapeutics?
The stock symbol for Allogene Therapeutics is "ALLO."
What Is the Allogene Therapeutics Market Cap?
As of today, Allogene Therapeutics market cap is 522.900M USD.
What Is Allogene Therapeutics's Earnings Per Share (TTM)?
The Allogene Therapeutics EPS (TTM) is -0.865.
When Is the Next Allogene Therapeutics Earnings Date?
Allogene Therapeutics will release its next earnings report on May 06, 2026.
From a Technical Analysis Perspective, Is ALLO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Allogene Therapeutics Stock Split?
Allogene Therapeutics has split 0 times.
How Many Employees Does Allogene Therapeutics Have?
Allogene Therapeutics has 151 employees.
What is the current trading status of Allogene Therapeutics (ALLO)?
As of Apr 15, 2026, Allogene Therapeutics (ALLO) is trading at a price of 2.170 USD, with a previous close of 2.280 USD. The stock has fluctuated within a day range of 1.850 USD to 2.175 USD, while its 52-week range spans from 0.862 USD to 4.460 USD.
What Is Allogene Therapeutics (ALLO) Price Target According to Analysts?
The average 12-month price target for Allogene Therapeutics is 8.050 USD, with a high estimate of 14 USD and a low estimate of 1.6 USD. 13 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +270.97% Upside potential.
What Is the ALLO Premarket Price?
ALLO's last pre-market stock price is 1.900 USD. The pre-market share volume is 7,980,000.000, and the stock has decreased by -0.380, or -16.670%.
What Is the ALLO After Hours Price?
ALLO's last after hours stock price is 2.150 USD, the stock has decreased by -0.020, or -0.920%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.